business
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
SHANGHAI and HONG KONG, Sept. 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies,...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
UK Prime Minister Burnham says Iran 'played a part' in British air base incident
cnbc.com
Piyush Goyal gets a ‘trade minister for life’ tag from US trade chief at G20
timesofindia.indiatimes.com
Trump touts $200 billion South Korean investment plan as Alaska LNG project hangs in balance
cnbc.com
Cornell rape case: Prosecutor says he wasn't given transcript of Jane Doe's interview with campus police; university agrees to independent investigation, New York governor says
yahoo.com
Passengers and crew foil co-pilot's apparent attempt to crash FlyDubai flight to Israel
cnbc.com